JP2023516325A - 血中コレステロール低下用、心血管代謝疾患の予防又は治療用及び抗炎症用薬学的組成物 - Google Patents
血中コレステロール低下用、心血管代謝疾患の予防又は治療用及び抗炎症用薬学的組成物 Download PDFInfo
- Publication number
- JP2023516325A JP2023516325A JP2022552511A JP2022552511A JP2023516325A JP 2023516325 A JP2023516325 A JP 2023516325A JP 2022552511 A JP2022552511 A JP 2022552511A JP 2022552511 A JP2022552511 A JP 2022552511A JP 2023516325 A JP2023516325 A JP 2023516325A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cap1
- amino acid
- acid sequence
- pcsk9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 116
- 210000004369 blood Anatomy 0.000 title claims abstract description 55
- 239000008280 blood Substances 0.000 title claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 49
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 40
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 15
- 102100027241 Adenylyl cyclase-associated protein 1 Human genes 0.000 claims abstract description 240
- 230000027455 binding Effects 0.000 claims abstract description 147
- 239000003112 inhibitor Substances 0.000 claims abstract description 100
- 230000014509 gene expression Effects 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 101150077194 CAP1 gene Proteins 0.000 claims abstract description 39
- 102000007156 Resistin Human genes 0.000 claims abstract description 38
- 108010047909 Resistin Proteins 0.000 claims abstract description 38
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 229940122498 Gene expression inhibitor Drugs 0.000 claims abstract description 19
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 2
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 claims description 236
- 150000001413 amino acids Chemical group 0.000 claims description 185
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 230000015556 catabolic process Effects 0.000 claims description 38
- 238000006731 degradation reaction Methods 0.000 claims description 38
- 235000018102 proteins Nutrition 0.000 claims description 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 34
- 108020004459 Small interfering RNA Proteins 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 20
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 17
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 17
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 108091023037 Aptamer Proteins 0.000 claims description 14
- 239000000816 peptidomimetic Substances 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 108091070501 miRNA Proteins 0.000 claims description 11
- 239000002679 microRNA Substances 0.000 claims description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 11
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 8
- 101710172072 Kexin Proteins 0.000 claims description 7
- 108090000787 Subtilisin Proteins 0.000 claims description 7
- 210000003494 hepatocyte Anatomy 0.000 claims description 7
- 239000013610 patient sample Substances 0.000 claims description 7
- 108010057466 NF-kappa B Proteins 0.000 claims description 4
- 102000003945 NF-kappa B Human genes 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 210000005228 liver tissue Anatomy 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract description 178
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 108010077333 CAP1-6D Proteins 0.000 abstract 4
- 108010031970 prostasin Proteins 0.000 abstract 4
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 176
- 102000000853 LDL receptors Human genes 0.000 description 89
- 108010001831 LDL receptors Proteins 0.000 description 88
- 210000004027 cell Anatomy 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- 102000009193 Caveolin Human genes 0.000 description 16
- 108050000084 Caveolin Proteins 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- 108010019874 Clathrin Proteins 0.000 description 15
- 102000005853 Clathrin Human genes 0.000 description 15
- 229930193282 clathrin Natural products 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 11
- 102000003727 Caveolin 1 Human genes 0.000 description 10
- 108090000026 Caveolin 1 Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000012202 endocytosis Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 9
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 8
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000001163 endosome Anatomy 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003125 immunofluorescent labeling Methods 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 230000006674 lysosomal degradation Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102100023078 Early endosome antigen 1 Human genes 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 108010037434 early endosome antigen 1 Proteins 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- 210000003712 lysosome Anatomy 0.000 description 5
- 230000001868 lysosomic effect Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 4
- 238000000749 co-immunoprecipitation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000001906 cholesterol absorption Effects 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102200055975 rs505151 Human genes 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001125574 Homo sapiens Prostasin Proteins 0.000 description 2
- 101000686909 Homo sapiens Resistin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100022873 Ras-related protein Rab-11A Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004323 caveolae Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000047406 human CAP1 Human genes 0.000 description 2
- 102000053786 human PCSK9 Human genes 0.000 description 2
- 102000056685 human RETN Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010403 protein-protein docking Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 102200101888 rs72556279 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710084382 Cyclase-associated protein 1 Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100135844 Homo sapiens PCSK9 gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101150060955 RAB11A gene Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700039148 rab11 Proteins 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Abstract
Description
本明細書において使用される用語「健康機能食品」とは、人体に有用な機能性を有する原料や成分を使用して錠剤、カプセル、粉末、顆粒、液状及び丸薬などの形態で製造及び加工した食品をいう。ここで、機能性とは、人体の構造及び機能に対して栄養素を調節したり、生理学的作用などのような保健用途に有用な効果を得ることを意味する。本発明の健康機能食品は、当業界において通常使用される方法によって製造可能であり、前記製造時には、当業界で通常添加する原料及び成分を添加して製造することができる。また、一般薬品とは異なって、食品を原料として薬品の長期服用時に発生しうる副作用などがない長所があり、携帯性に優れていて、本発明の健康機能食品は、抗代謝性疾患効果を増進させるための補助剤として摂取が可能である。
マウス肝組織で免疫沈降法(immunoprecipitation)を用いてCAP1及びPCSK9の間の物理的相互作用を確認した(図1a)。ファーウェスタンブロット(far-western blot)分析のために、非還元条件下に精製されたmFc-CAP1又はHis-PCSK9をプレイ(prey)として使用し、それぞれに対するベイト(bait)としてHis-PCSK9又はmFc-CAP1を使用した(図1b)。生細胞で上記のような相互作用を可視化するために、各断片に融合したタンパク質間相互作用によって一緒に集まる蛍光タンパク質の二つの非蛍光断片の間の相補性に基づく二分子蛍光補完分析(Bimolecular fluorescence complementation assay)を行った。これを通じて、hCAP1とhPCSK9の間の直接的な結合を明確に可視化した。図1cに示されたように、CAP1及びPCSK9がそれぞれの断片(pVC155及びpVN173)に融合し、両方とも発現するとき、緑色蛍光が観察された(左パネル)。しかしながら、ヒトCAP1又はPCSK9が単独で発現するとき、蛍光は検出されなかった(それぞれ中間及び右パネル)。
本発明者らは、ヒト遺伝子研究で発見されたよく知られた機能損失及び機能獲得変異を含むPCSK9-CRDの部位特異的突然変異誘導(site-directed mutagenesis)によって8個のPCSK9点突然変異体(point mutants)を生成した(図2a;矢印は点突然変異の誘発地点)。HepG2細胞でPCSK9のQ544E及びH683fs突然変異体は発現せず、これは、これらの突然変異体がタンパク質の発現又は安定性と関連があることを示唆する。
(3.1.siRNAを用いたCAP1発現抑制効果の研究)
HepG2細胞でPCSK9処理は、用量依存的にLDL受容体の分解を促進させる。本発明者らは、CAP1の発現抑制がLDL受容体の分解に及ぼす影響を調べてみるために、CAP1遺伝子をsiRNAを用いて発現を抑制させた。siRNA配列は、下記の通りである:
生体内(in vivo)でCAP1の役割を調べてみるために、TALEN(Transcription activator-like effector nuclease)を利用してCAP1エクソン3を標的化したCAP1ノックアウト(knock-out)マウスを生成した。同型接合ノックアウトマウスは、胚16.5日目に死亡したため、異種接合ノックアウトマウス(CAP1+/-マウス)を使用した。CAP1+/-マウスの臓器(organs)は、最大約16週まで野生型マウスの臓器と変わらないが、CAP1のmRNA及びタンパク質レベルは、CAP1+/-マウスの多様な臓器で顕著に減少することが示された(図3d)。これによって、本発明者は、高脂肪食(high-fat diet)を摂取又は摂取しないCAP1+/-マウス及びCAP1+/+マウスの肝でLDL受容体及びPCSK9の発現レベルを比較した。rt-PCRを通したLDL受容体のmRNA発現の調査では有意差を確認できなかったが、LDL受容体のタンパク質レベルは、CAP1+/+マウスよりもCAP1+/-マウスで顕著に高かった(図3e)。前記結果によって、高脂肪食下においてCAP1+/-マウスは、野生型マウスと比較してさらに低い総コレステロールとLDLコレステロール数値を有していることが確認された(図3f)。血漿トリグリセリド(triglyceride,TG)及び高密度リポタンパク質(HDL)のコレステロールのレベルには有意差がなかった。
LDL受容体のPCSK9媒介性分解は、リソソームプロテアーゼ抑制剤(E-64d)により独占的に遮断されたが、プロテアソーム(proteasome;lactacystin)又はオートファジー(autophagy;bafilomycin)の抑制剤によって遮断されず、これは、LDL受容体が、従来報告されたように、リソソーム経路によって分解されることを示唆する。このような発見は、また、Cy3染料がコンジュゲートされたPCSK9(PCSK9-Cy3)を処理したHepG2細胞でPCSK9-Cy3、エンドソームマーカーEEA1(early endosome antigen 1)及びリソソームマーカーLAMP2(lysosome-associated membrane protein 2)を有するLDL受容体を多様な時点で追跡することによって説明された。すなわち、PCSK9-Cy3処理後、30分内に、EEA1は、PCSK9及びLDL受容体とともに局在化(co-localization)された(図4a)。次いで、60分内にPCSK9及びLDL受容体とともに局在化されるLAMP2が現れた(図4b)。これは、PCSK9及びLDL受容体が消えた240分まで増加した(図4a及び4c)。このような初期エンドソーム形成でないリソソーム形成は、CAP1枯渇によって遮断された(図4d)。
本発明によるhFc-CAP1は、配列番号4のアミノ酸配列によってタンパク質合成メーカに依頼して作製した。mFc-CAP1の発現のために、pCEP4発現ベクターを用いた。
ヒト単核球細胞株THP-1細胞は、ATCC(American type culture collection、米国)社の培養方法によって1X抗菌-抗真菌剤(antibiotic-antimycotic;Gibco、15240-062、米国)及び10%FBS(fetal bovine serum)を含有するRPMI培地で温度37℃、CO2分圧5%が維持される培養器で培養した。以後、THP-1細胞をRPMI培地に希釈した後、各well当たり1×106cellsで細胞を均一に加え、37℃、5%CO2環境の培養器で24時間の間培養した。
(7.1.HepG2ヒト肝がん細胞の培養)
HepG2細胞は、ATCC社の培養方法によって1X抗菌-抗真菌剤(Gibco)及び10%FBSを含有するDMEM(Dulbecco’s Modified Eagle’s medium、high glucose)培地で温度37℃、CO2分圧5%が維持される培養器で培養した。以後、HepG2細胞をDMEM培地に希釈した後、各well当たり5×105cellsで細胞を均一に加え、37℃、5%CO2環境の培養器で24時間の間培養した。
HepG2細胞を基本(basal)DMEMとして37℃、5%CO2培養器で6時間の間培養した。その後、前記細胞に2μg/ml組換えヒトPCSK9と各濃度(0.1、1μg/ml又は0.05、0.15、0.5μg/ml)別にmFc-CAP1を同時に4時間の間処理した。以後、細胞溶解バッファー(CST、#9803)を用いてHepG2細胞からタンパク質を分離し、これを電気泳動した後、タンパク質をPVDF膜(polyvinylidene fluoride membrane;Millipore、米国)にトランスファーした後、各抗体を反応させた。
HepG2細胞に50ng/mlのrhレジスチンと各濃度(0.1、1μg/ml又は0.05、0.15、0.5μg/ml)別にmFc-CAP1を処理し、37℃、5%CO2培養器で12~16時間の間培養した。以後、前記実施例7.2と同じ方法によってタンパク質を得て、電気泳動した後、それぞれに特異的な抗体と反応させた。
培養中のHepG2細胞を基本DMEM培地に変えた後、37℃、5%CO2培養器で6時間の間培養した。6時間後、AMPK活性剤であるAICAR(5-aminoimidazole-4-carboxamide riboside)を1時間の間前処理した後、50ng/mlのrhレジスチンと各濃度(0.05、0.5μg/ml)別にmFc-CAP1を4時間の間共に処理した。
本発明によるmFc-CAP1のLDLコレステロール吸収抑制効果を直接確認するために、本発明者らは、shRNAを用いてヒト臍帯静脈内皮細胞でのCAP1遺伝子発現を抑制させた。CAP1遺伝子をターゲットするようにデザインされた下記の配列番号9のshCAP1は、pLL3.7レンチウイルスベクターのHpaI及びXhoI制限酵素部位でクローニングして製造した。
Claims (47)
- 配列番号1のアミノ酸配列からなるCAP1(adenylyl cyclase-associated protein 1)と配列番号2のアミノ酸配列からなるPCSK9(proprotein convertase subtilisin/kexin type-9)の間の結合阻害剤を有効成分として含む、血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、CAP1又はPCSK9に特異的に結合するタンパク質、ペプチド、ペプチド模倣体、基質類似体、アプタマー及び抗体からなる群から選ばれる1種以上であることを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、配列番号1のアミノ酸配列からなるCAP1タンパク質又はその断片;及び免疫グロブリン重鎖のFc断片を含む融合タンパク質であることを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 前記融合タンパク質が、配列番号4又は配列番号6のアミノ酸配列からなることを特徴とする、請求項3に記載の血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、CAP1のSH3(Src homology 3)結合ドメイン及びPCSK9のシステインリッチドメイン(cysteine rich domain;CRD)からなる群から選ばれる一つ以上のドメインに結合することを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 前記CAP1のSH3結合ドメインが、配列番号10のアミノ酸配列からなることを特徴とする、請求項5に記載の血中コレステロール低下用薬学的組成物。
- 前記PCSK9のシステインリッチドメインが、配列番号11のアミノ酸配列からなることを特徴とする、請求項5に記載の血中コレステロール低下用薬学的組成物。
- 前記PCSK9のシステインリッチドメインが、配列番号12のアミノ酸配列からなるM1ドメインを含むことを特徴とする、請求項5に記載の血中コレステロール低下用薬学的組成物。
- 前記PCSK9のシステインリッチドメインが、配列番号13のアミノ酸配列からなるM3ドメインを含むことを特徴とする、請求項5に記載の血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、CAP1のSH3結合ドメインに存在する34B番アスパラギン酸(aspartic acid)を含む部位に特異的に結合することを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、PCSK9のM1ドメインに存在する494番リシン(lysine)を含む部位に特異的に結合することを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 前記結合阻害剤が、PCSK9のM3ドメインに存在する659番アルギニン(arginine)を含む部位に特異的に結合することを特徴とする、請求項1に記載の血中コレステロール低下用薬学的組成物。
- 配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤を有効成分として含む、血中コレステロール低下用薬学的組成物。
- 前記発現抑制剤が、CAP1遺伝子のmRNAに相補的に結合できるアンチセンスヌクレオチド、siRNA、shRNA、miRNA、リボザイム及びPNAからなる群から選ばれる1種以上であることを特徴とする、請求項13に記載の血中コレステロール低下用薬学的組成物。
- 前記発現抑制剤が、配列番号8の塩基配列からなるsiRNAであることを特徴とする、請求項13に記載の血中コレステロール低下用薬学的組成物。
- 前記発現抑制剤が、配列番号9の塩基配列からなるshRNAであることを特徴とする、請求項13に記載の血中コレステロール低下用薬学的組成物。
- 前記組成物が、LDL(Low-density lipoprotein)受容体の分解を抑制することを特徴とする、請求項1又は13に記載の血中コレステロール低下用薬学的組成物。
- 前記コレステロールが、LDLコレステロールであることを特徴とする、請求項1又は13に記載の血中コレステロール低下用薬学的組成物。
- (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤;又は
(iii)前記(i)及び(ii)の混合物を含む、血中コレステロール低下用健康機能食品組成物。 - (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤;又は
(iii)前記(i)及び(ii)の混合物を含む、心血管代謝疾患の予防又は治療用薬学的組成物。 - 前記結合阻害剤が、CAP1又はPCSK9に特異的に結合するタンパク質、ペプチド、ペプチド模倣体、基質類似体、アプタマー及び抗体からなる群から選ばれる1種以上であることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記結合阻害剤が、配列番号1のアミノ酸配列からなるCAP1タンパク質又はその断片;及び免疫グロブリン重鎖のFc断片を含む融合タンパク質であることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記融合タンパク質が、配列番号4又は配列番号6のアミノ酸配列からなることを特徴とする、請求項22に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記発現抑制剤が、CAP1遺伝子のmRNAに相補的に結合できるアンチセンスヌクレオチド、siRNA、shRNA、miRNA、リボザイム及びPNAからなる群から選ばれる1種以上であることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記発現抑制剤が、配列番号8の塩基配列からなるsiRNAであることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記発現抑制剤が、配列番号9の塩基配列からなるshRNAであることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- 前記心血管代謝疾患が、糖尿病、肥満、脂質異常症、脂肪肝、高血圧、痛風、脳卒中、動脈硬化症、心筋梗塞症、狭心症、末梢血管疾患及びこれらの組み合わせからなる群から選ばれる疾患であることを特徴とする、請求項20に記載の心血管代謝疾患の予防又は治療用薬学的組成物。
- (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤;又は
(iii)前記(i)及び(ii)の混合物を含む、心血管代謝疾患の予防又は改善用健康機能食品組成物。 - (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列からなるCAP1と配列番号3のアミノ酸配列からなるレジスチン(resistin)の間の結合阻害剤;及び
(iii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤からなる群から選ばれる1種以上を有効成分として含む、抗炎症用薬学的組成物。 - 前記(i)の結合阻害剤が、PCSK9に特異的に結合するタンパク質、ペプチド、ペプチド模倣体、基質類似体、アプタマー及び抗体からなる群から選ばれる1種以上であることを特徴とする、請求項29に記載の抗炎症用薬学的組成物。
- 前記(ii)の結合阻害剤が、レジスチンに特異的に結合するタンパク質、ペプチド、ペプチド模倣体、基質類似体、アプタマー及び抗体からなる群から選ばれる1種以上であることを特徴とする、請求項29に記載の抗炎症用薬学的組成物。
- 前記(i)又は(ii)の結合阻害剤が、配列番号1のアミノ酸配列からなるCAP1タンパク質又はその断片;及び免疫グロブリン重鎖のFc断片を含む融合タンパク質であることを特徴とする、請求項29に記載の抗炎症用薬学的組成物。
- 前記融合タンパク質が、配列番号4又は配列番号6のアミノ酸配列からなることを特徴とする、請求項32に記載の抗炎症用薬学的組成物。
- 前記(iii)の発現抑制剤が、CAP1遺伝子のmRNAに相補的に結合できるアンチセンスヌクレオチド、siRNA、shRNA、miRNA、リボザイム及びPNAからなる群から選ばれる1種以上であることを特徴とする、請求項29に記載の抗炎症用薬学的組成物。
- 前記組成物が、NF-κBの活性を抑制することを特徴とする、請求項29に記載の抗炎症用薬学的組成物。
- 配列番号1のアミノ酸配列からなるCAP1と;配列番号2のアミノ酸配列からなるPCSK9又は配列番号3のアミノ酸配列からなるレジスチンの間の結合レベルを測定する製剤を含む、高コレステロール血症又は心血管代謝疾患の診断用組成物。
- 患者の試料のうち、配列番号1のアミノ酸配列からなるCAP1と;配列番号2のアミノ酸配列からなるPCSK9又は配列番号3のアミノ酸配列からなるレジスチンの間の結合レベルを測定する段階を含む、高コレステロール血症又は心血管代謝疾患診断のための情報提供方法。
- 前記患者の試料が、肝組織、肝細胞、血液、血清、血漿、唾液、喀痰及び尿からなる群から選ばれることを特徴とする、請求項37に記載の高コレステロール血症又は心血管代謝疾患診断のための情報提供方法。
- 下記の段階を含む高コレステロール血症又は心血管代謝疾患治療剤のスクリーニング方法:
(a)配列番号1のアミノ酸配列からなるCAP1タンパク質又はその断片;及び配列番号2のアミノ酸配列からなるPCSK9タンパク質又はその断片、又は配列番号3のアミノ酸配列からなるレジスチンタンパク質又はその断片;を含む試料に被検物質を処理する段階;
(b)前記CAP1;及びPCSK9タンパク質又はその断片、又はレジスチンタンパク質又はその断片;間の結合レベルを測定する段階;及び
(c)前記結合レベルが対照群試料と比較して減少した被検物質を選別する段階。 - 配列番号1のアミノ酸配列からなるCAP1(adenylyl cyclase-associated protein 1)と配列番号2のアミノ酸配列からなるPCSK9(proprotein convertase subtilisin/kexin type-9)の間の結合阻害剤を個体に投与する段階を含む、血中コレステロール低下方法。
- 配列番号1のアミノ酸配列からなるCAP1(adenylyl cyclase-associated protein 1)と配列番号2のアミノ酸配列からなるPCSK9(proprotein convertase subtilisin/kexin type-9)の間の結合阻害剤の、血中コレステロール低下用途。
- 配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1(adenylyl cyclase-associated protein 1)遺伝子の発現抑制剤を個体に投与する段階を含む、血中コレステロール低下方法。
- 配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1(adenylyl cyclase-associated protein 1)遺伝子の発現抑制剤の、血中コレステロール低下用途。
- (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤;又は
(iii)前記(i)及び(ii)の混合物を含む組成物を個体に投与する段階を含む、心血管代謝疾患の予防又は治療方法。 - (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤;又は
(iii)前記(i)及び(ii)の混合物を含む組成物の、心血管代謝疾患の予防又は治療用途。 - (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列からなるCAP1と配列番号3のアミノ酸配列からなるレジスチン(resistin)の間の結合阻害剤;及び
(iii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤からなる群から選ばれる1種以上を有効成分として含む組成物を個体に投与する段階を含む、炎症抑制方法。 - (i)配列番号1のアミノ酸配列からなるCAP1と配列番号2のアミノ酸配列からなるPCSK9の間の結合阻害剤;
(ii)配列番号1のアミノ酸配列からなるCAP1と配列番号3のアミノ酸配列からなるレジスチン(resistin)の間の結合阻害剤;及び
(iii)配列番号1のアミノ酸配列をコードする塩基配列からなるCAP1遺伝子の発現抑制剤からなる群から選ばれる1種以上を有効成分として含む組成物の、炎症抑制用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200026073 | 2020-03-02 | ||
KR10-2020-0026073 | 2020-03-02 | ||
PCT/KR2020/010925 WO2021177518A1 (ko) | 2020-03-02 | 2020-08-14 | 혈중 콜레스테롤 저하용, 심혈관 대사질환의 예방 또는 치료용 및 항염용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023516325A true JP2023516325A (ja) | 2023-04-19 |
Family
ID=77613515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022552511A Pending JP2023516325A (ja) | 2020-03-02 | 2020-08-14 | 血中コレステロール低下用、心血管代謝疾患の予防又は治療用及び抗炎症用薬学的組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230159601A1 (ja) |
JP (1) | JP2023516325A (ja) |
KR (1) | KR20220151176A (ja) |
AU (1) | AU2020433744A1 (ja) |
CA (1) | CA3170560A1 (ja) |
WO (1) | WO2021177518A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023051822A1 (zh) * | 2021-09-30 | 2023-04-06 | 北京安龙生物医药有限公司 | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 |
KR20230066257A (ko) * | 2021-11-05 | 2023-05-15 | 서울대학교병원 | 리지스틴 특이적 항체 및 이의 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0223272D0 (en) * | 2002-10-08 | 2002-11-13 | Oxford Glycosciences Uk Ltd | A protein involved in therapy |
CN102448990A (zh) * | 2009-03-30 | 2012-05-09 | 普罗塔布有限公司 | 腺苷酸环化酶相关蛋白(cap1)及其作为免疫调节靶标的应用 |
KR101473526B1 (ko) * | 2011-08-08 | 2014-12-22 | 서울대학교병원 | 인간 리지스틴 수용체 및 그 용도 |
KR102040974B1 (ko) * | 2017-01-31 | 2019-11-06 | 서울대학교병원 | Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물 |
-
2020
- 2020-08-14 KR KR1020227033978A patent/KR20220151176A/ko active Search and Examination
- 2020-08-14 WO PCT/KR2020/010925 patent/WO2021177518A1/ko active Application Filing
- 2020-08-14 AU AU2020433744A patent/AU2020433744A1/en active Pending
- 2020-08-14 JP JP2022552511A patent/JP2023516325A/ja active Pending
- 2020-08-14 US US17/905,461 patent/US20230159601A1/en active Pending
- 2020-08-14 CA CA3170560A patent/CA3170560A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3170560A1 (en) | 2021-09-10 |
KR20220151176A (ko) | 2022-11-14 |
WO2021177518A1 (ko) | 2021-09-10 |
AU2020433744A1 (en) | 2022-09-22 |
US20230159601A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Amyloid β interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier | |
US20130252821A1 (en) | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state | |
KR20160074000A (ko) | 암 모델 및 관련 방법 | |
CN110023332B (zh) | 包含sasp调节剂和衰老衰减剂的组合物及其用于调节细胞衰老的用途 | |
CA2643048A1 (en) | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor | |
MX2012009318A (es) | Metodos y compuestos para el crecimiento muscular. | |
Kim et al. | Protein kinase Cdelta is associated with 14-3-3 phosphorylation in seizure-induced neuronal death | |
JP2023516325A (ja) | 血中コレステロール低下用、心血管代謝疾患の予防又は治療用及び抗炎症用薬学的組成物 | |
US20210087247A1 (en) | Mps peptides and use thereof | |
AU2013326552B2 (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein | |
US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
WO2020168850A1 (zh) | Ube3a泛素化PP2A激活因子PTPA在治疗天使综合症和孤独症中的应用 | |
US20220332813A1 (en) | Compositions and methods for treatment and prevention of alzheimer's disease | |
TWI359271B (en) | Pharmaceutical composition for insulin resistance | |
TWI609692B (zh) | 新穎stip1多肽及其用途 | |
IL179555A (en) | Use of argonionine to prepare a medical preparation for the treatment and / or prevention of autoimmune diseases | |
JP2016104716A (ja) | 膵臓癌治療用のcd95シグナル伝達阻害化合物 | |
KR101511737B1 (ko) | Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물 | |
US9255272B2 (en) | Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma | |
WO2022192528A1 (en) | Gal3bp polypeptide compositions and methods for treatment of cancer and determining treatment responsiveness | |
Paudel | Epithelial Sodium Channel in Human Arteries–an Emerging Player in Blood Pressure Regulation | |
WO2015051279A2 (en) | Cxcr4 up- and down-regulation for treatment of diseases or disorders | |
KR20230172930A (ko) | 신경 세포 성장 조절 인자 1(negr1) 유래 펩타이드를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 | |
US20070009509A1 (en) | Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor | |
Dhyani | POST-TRANSCRIPTIONAL MODULATORS OF LDL-R IN LIPID METABOLISM AND ATHEROSCLEROSIS-ANIMAL AND HUMAN STUDIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221025 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221025 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20221025 Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20221025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240507 |